Travers Karin, Martin Amber, Khankhel Zarmina, Boye Kristina S, Lee Lauren J
United BioSource Corporation, Lexington, MA.
Int J Nephrol Renovasc Dis. 2013;6:1-13. doi: 10.2147/IJNRD.S30894. Epub 2013 Jan 3.
Chronic kidney disease (CKD) is a common disorder with increasing prevalence worldwide. This systematic literature review aims to provide insights specific to Japan regarding the burden and treatment of CKD.
We reviewed English and Japanese language publications from the last 10 years, reporting economic, clinical, humanistic, and epidemiologic outcomes, as well as treatment patterns and guidelines on CKD in Japan.
This review identified 85 relevant articles. The prevalence of CKD was found to have increased in Japan, attributable to multiple factors, including better survival on dialysis therapy and a growing elderly population. Risk factors for disease progression differed depending on CKD stage, with proteinuria, smoking, hypertension, and low levels of high-density lipoprotein commonly associated with progression in patients with stage 1 and 2 disease. Serum albumin levels and hemoglobin were the most sensitive variables to progression in patients with stage 3 and 5 disease, respectively. Economic data were limited. Increased costs were associated with disease progression, and with peritoneal dialysis as compared with either hemodialysis or combination therapy (hemodialysis + peritoneal dialysis) treatment options. Pharmacological treatments were found potentially to improve quality of life and result in cost savings. We found no reports of treatment patterns in patients with early-stage CKD; however, calcium channel blockers were the most commonly prescribed antihypertensive agents in hemodialysis patients. Treatment guidelines focused on anemia management related to dialysis and recommendations for peritoneal dialysis treatment and preventative measures. Few studies focused on humanistic burden in Japanese patients; Japanese patients reported greater disease burden but better physical functioning compared with US and European patients.
A dearth of evidence regarding the earlier stages of kidney disease presents an incomplete picture of CKD disease burden in Japan. Further research is needed to gain additional insight into CKD in Japan.
慢性肾脏病(CKD)是一种常见疾病,在全球范围内的患病率呈上升趋势。本系统文献综述旨在提供有关日本CKD负担和治疗的具体见解。
我们回顾了过去10年的英文和日文出版物,报告了日本CKD的经济、临床、人文和流行病学结果,以及治疗模式和指南。
本综述确定了85篇相关文章。发现日本CKD的患病率有所上升,这归因于多种因素,包括透析治疗生存率提高和老年人口增加。疾病进展的危险因素因CKD阶段而异,蛋白尿、吸烟、高血压和高密度脂蛋白水平低通常与1期和2期疾病患者的疾病进展相关。血清白蛋白水平和血红蛋白分别是3期和5期疾病患者疾病进展最敏感的变量。经济数据有限。成本增加与疾病进展以及腹膜透析有关,与血液透析或联合治疗(血液透析+腹膜透析)治疗方案相比。发现药物治疗可能改善生活质量并节省成本。我们没有找到关于早期CKD患者治疗模式的报告;然而,钙通道阻滞剂是血液透析患者最常用的抗高血压药物。治疗指南侧重于与透析相关的贫血管理以及腹膜透析治疗和预防措施的建议。很少有研究关注日本患者的人文负担;与美国和欧洲患者相比,日本患者报告的疾病负担更大,但身体功能更好。
关于肾脏疾病早期阶段的证据不足,这使得日本CKD疾病负担的情况不完整。需要进一步研究以深入了解日本的CKD。